Clevidipine: A new intravenous option for the management of acute hypertension

Author:

Ndefo Uche Anadu1,Erowele Goldina Ikezuagu2,Ebiasah Ruth3,Green Wendy4

Affiliation:

1. Department of Pharmacy Practice, Texas Southern University, Houston

2. Formulary Management and Pharmacoeconomic Services, Harris County Hospital District, Houston

3. Holy Cross Hospital, Silver Spring, MD

4. Formulary Management and Pharmacoeconomic Services, Harris County Hospital District

Publisher

Oxford University Press (OUP)

Subject

Health Policy,Pharmacology

Reference28 articles.

1. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report;Chobanian;JAMA,2003

2. Heart disease and stroke statistics: 2007 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee;Rosamond;Circulation,2007

3. Hypertensive crises: challenges and management;Marik;Chest,2007

4. Treatment of acute severe hypertension: current and newer agents;Varon;Drugs,2008

5. Food and Drug Administration. Approval letter for Cleviprex (clevidipine butyrate). NDA approval letter. www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022156s000_Approv.pdf (accessed 2009 Nov 23).

Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3